In July 2017, Genoa Pharmaceuticals changed its corporate name to Avalyn Pharma (Avalyn is old English for a "beautiful breath of life"). Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
